Last updated on February 2015

A phase III randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of lebrikizumab in patients with persistent moderate to severe atopic dermatitis that is inadequately controlled by topical corticosteroids


Brief description of study

A phase III randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of lebrikizumab in patients with persistent moderate to severe atopic dermatitis that is inadequately controlled by topical corticosteroids

Detailed Study Description

This is a 22 week study with 10 visits for the treatment of atopic dermatitis.

Clinical Study Identifier: TX140085

Contact Investigators or Research Sites near you

Start Over

Janice K. Orem, CMA

Dermatology Clinical Research Center of San Antonio
San Antonio, TX USA
  Connect »